Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

51.82
+0.92001.81%
Volume:334.83K
Turnover:17.17M
Market Cap:2.16B
PE:-16.86
High:52.06
Open:50.79
Low:49.70
Close:50.90
Loading ...

Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?

Zacks
·
Yesterday

Tarsus Pharmaceuticals to present abstracts on XDEMVY at ASCRS meeting

TIPRANKS
·
22 Apr

Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting

GlobeNewswire
·
22 Apr

Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

Business Wire
·
22 Apr

With Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) It Looks Like You'll Get What You Pay For

Simply Wall St.
·
02 Apr

Oppenheimer Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
28 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx

Reuters
·
13 Mar

Sector Update: Health Care Stocks Flat to Lower Premarket Thursday

MT Newswires Live
·
13 Mar

BUZZ-Tarsus Pharma dips after upsized $125 mln stock offering

Reuters
·
13 Mar

Tarsus Pharmaceuticals Prices Upsized $125 Million Equity Offering

MT Newswires Live
·
13 Mar

Tarsus Pharmaceuticals Inc : Jefferies Raises Target Price to $58 From $54

THOMSON REUTERS
·
07 Mar

Tarsus Pharmaceuticals Is Maintained at Buy by Jefferies

Dow Jones
·
07 Mar

Tarsus to Participate in Upcoming Investor Conference

GlobeNewswire
·
07 Mar

Tarsus Pharmaceuticals price target raised to $58 from $54 at Jefferies

TIPRANKS
·
07 Mar

Barclays Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
06 Mar

Tarsus Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
27 Feb

Stock Track | Tarsus Pharmaceuticals Soars 5.74% as Strong 2024 Results Fuel Growth Momentum

Stock Track
·
26 Feb

Tarsus Pharmaceuticals Price Target Maintained With a $73.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Feb

Tarsus Pharmaceuticals: Strong Earnings and Growth Potential Make It a Buy

TIPRANKS
·
26 Feb

Tarsus Pharmaceuticals: Undervalued Growth Potential and Acquisition Appeal Reinforce Buy Rating

TIPRANKS
·
26 Feb